Press Releases
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
July 2023
Qihan Biotech announced today that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a.
Qihan Biotech Appoints Yingyong Xu to its Chief Medical Officer
May 2024
Qihan Biotech today announced the appointment of Mr. Yingyong Xu as the Chief Medical Officer.
Qihan Biotech Appoints Tony W. Ho to its Board of Directors
October 2022
Qihan Biotech today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director.
Media Coverage
January 2021
Timmerman Report
Publications